Evidence map›Paper›PMID 39339925›Full record

ArticleViruses2024

Mapping Transmission Dynamics and Drug Resistance Surveillance in the Cyprus HIV-1 Epidemic (2017-2021).

Cicek Topcu, Bram Vrancken, Johana Hezka Rodosthenous, David van de Vijver, Georgios Siakallis, Philippe Lemey, Leondios G Kostrikis

Abstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cicek TopcuLaboratory of Biotechnology and Molecular Virology, Department of Biological Sciences, University of Cyprus, 2109 Nicosia, Cyprus.ORCID 0000-0002-9641-7737
Bram VranckenSpatial Epidemiology Lab (SpELL), Université Libre de Bruxelles, 1050 Bruxelles, Belgium.ORCID 0000-0001-6547-5283
Johana Hezka RodosthenousLaboratory of Biotechnology and Molecular Virology, Department of Biological Sciences, University of Cyprus, 2109 Nicosia, Cyprus.
David van de VijverDepartment of Viroscience, Erasmus University Medical Centre, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0001-5877-8526
Georgios SiakallisAIDS Clinic, Larnaca General Hospital, 6043 Larnaca, Cyprus.
Philippe LemeyLaboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0003-2826-5353
Leondios G KostrikisLaboratory of Biotechnology and Molecular Virology, Department of Biological Sciences, University of Cyprus, 2109 Nicosia, Cyprus.ORCID 0000-0002-5340-7109

Funding

Cyprus Academy of Sciences, Letters, and Arts Internal FundsEuropean Regional Development Fund and the Republic of Cyprus through the Research and Innovation Foundation EXCELLENCE/0918/0093Ministry of Health of the Republic of Cyprus 240/2019University of Cyprus Internal Funds
6 · The paper itself

Abstract

The human immunodeficiency virus type 1 (HIV-1) epidemic has been a major public health threat on a global scale since the early 1980s. Despite the introduction of combination antiretroviral therapy (cART), the incidence of new HIV-1 infections continues to rise in some regions around the world. Thus, with the continuous transmission of HIV-1 and the lack of a cure, it is imperative for molecular epidemiological studies to be performed, to monitor the infection and ultimately be able to control the spread of this virus. This work provides a comprehensive molecular epidemiological analysis of the HIV-1 infection in Cyprus, through examining 305 HIV-1 sequences collected between 9 March 2017 and 14 October 2021. Employing advanced statistical and bioinformatic techniques, the research delved deeply into understanding the transmission dynamics of the HIV-1 epidemic in Cyprus, as well as the monitoring of HIV-1's genetic diversity and the surveillance of transmitted drug resistance. The characterization of Cyprus's HIV-1 epidemic revealed a diverse landscape, comprising 21 HIV-1 group M pure subtypes and circulating recombinant forms (CRFs), alongside numerous uncharacterized recombinant strains. Subtypes A1 and B emerged as the most prevalent strains, followed by CRF02_AG. The findings of this study also revealed high levels of transmitted drug resistance (TDR) patterns, raising concerns for the efficacy of cART. The demographic profiles of individuals involved in HIV-1 transmission underscored the disproportionate burden borne by young to middle-aged Cypriot males, particularly those in the MSM community, who reported contracting the virus in Cyprus. An assessment of the spatiotemporal evolutionary dynamics illustrated the global interconnectedness of HIV-1 transmission networks, implicating five continents in the dissemination of strains within Cyprus: Europe, Africa, Asia, North America, and Oceania. Overall, this study advances the comprehension of the HIV-1 epidemic in Cyprus and highlights the importance of understanding HIV-1's transmission dynamics through continuous surveillance efforts. Furthermore, this work emphasizes the critical role of state-of-the-art bioinformatics analyses in addressing the challenges posed by HIV-1 transmission globally, laying the groundwork for public health interventions aimed at curbing its spread and improving patient outcomes.

Indexed as

Drug Resistance, ViralEpidemicsHIV-1HIV InfectionsPhylogenyAdolescentAdultAnti-HIV AgentsCyprusFemaleGenetic VariationGenotypeHumansMaleMiddle AgedMolecular EpidemiologyAnti-HIV AgentsCyprusHIV-1 molecular epidemiologyHIV-1 phylodynamicsHIV-1 phylogeneticsHIV-1 phylogeographicsHIV-1 transmitted drug resistancehuman immunodeficiency virus type 1 (HIV-1)

Identifiers

PMID39339925
PMCPMC11437465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.